Emerging drugs for the treatment of hidradenitis suppurativa

References

• von Laffert M, Stadie V, Wohlrab J, et al. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol. 2011;164:367.
   PubMed Web of Science ®Google Scholar
• Lim SYD, Oon HH. Systemic review of immunomodulatory therapies for hidradenitis suppurativa. Biologics. 2019 May;13(13):53–78.
   PubMedGoogle Scholar
• Garg a, Lavian J, Lin G, et al. Incidence of hidradenitis suppurativa in the United States: a sex- and age-adjusted population analysis. J Am Acad Dermatol. 2017;77:118.
   PubMed Web of Science ®Google Scholar
• von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2000;14:389.
   PubMed Web of Science ®Google Scholar
• Pink AE, Simpson MA, Desai N, et al. Mutations in the γ-secretase genes NCSTN, PSENEN, and PSEN1 underlie rare forms of hidradenitis suppurativa (acne inversa). J Invest Dermatol. 2012 Oct;132(10):2459–2461.
   PubMed Web of Science ®Google Scholar
• Revuz JE, Canoui-Poitrine F, Wolkenstein P, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies.m. J Am Acad Dermatol. 2008;59:596.
   PubMed Web of Science ®Google Scholar
• Shalom G, Freud T, Harman-Boehm I, et al. Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients. Br J Dermatol. 2015;173:464.
   PubMed Web of Science ®Google Scholar
• Yadav S, Singh S, Edakkanambeth Varayil J, et al. Hidradenitis suppurativa in patients with inflammatory bowel disease: a population-based cohort study in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2016 Jan;14(1):65–70. .
   PubMed Web of Science ®Google Scholar
• Kohorst JJ, Kimball AB, Davis MD. Systemic associations of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S27–35.
   PubMed Web of Science ®Google Scholar
• Hendricks AJ, Hsiao JL, Lowes MA, et al. A comparison of interventional management guidelines for hidradenitis suppurativa. Dermatology. 2019 Oct;23:1–16.
   Google Scholar
• Kouris a, Platsidaki E, Christodoulou C, et al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232:687.
   PubMed Web of Science ®Google Scholar
• Koceva I, Rummelein B, Gerber PA, et al. Fluorescent light energy: a new therapeutic approach to effectively treating acne conglobata and hidradenitis suppurativa. Clin Case Rep. 2019 Aug 10;7(9):1769–1772.
   PubMed Web of Science ®Google Scholar
• Jemec GBE, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol. 1996;35:191–194.
   PubMed Web of Science ®Google Scholar
• Rambhatla PV, Lim HW, Hamzavi I. a systematic review of treatments for Hidradenitis Suppurativa. Arch Dermatol. 2012;148(4):438–446.
   Google Scholar
• Tchero H, Herlin C, Bekara F, et al. Hidradenitis suppurativa: a systematic review and meta-analysis of therapeutic interventions. Indian J Dermatol Venereol Leprol. 2019;85:248–257.
   PubMed Web of Science ®Google Scholar
• Grant a, Gonzalez T, Montgomery MO, et al. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010 Feb;62(2):205–217.
   PubMed Web of Science ®Google Scholar
• Kerdel FR, Azevedo FA, Kerdel Don C, et al. Apremilast for the treatment of mild-to-moderate hidradenitis suppurativa in a prospective, open-label, phase 2 study. J Drugs Dermatol. 2019 Feb 1; 18(2):170–176.
   PubMed Web of Science ®Google Scholar
• Vossen ARJV, MBA VD, van der Zee HH, et al. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019 Jan;80(1):80–88.
   PubMed Web of Science ®Google Scholar
• Savage KT, Santillan MR, Flood KS, et al. Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep. 2020 Jan 20;6(2):99–102.
   PubMedGoogle Scholar
• Hotz C, Sbidian E, Ingen-Housz-Oro S, et al. Thalidomide in severe hidradenitis suppurativa: a therapeutic option. Acta Derm Venereol. 2019 Nov 1;99(12):1170–1171.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Step 3: clinical Research [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2018 Jan 4. cited 2020 Feb 10. Available from: https://www.fda.gov/patients/drug-development-process/step-3-clinical-research
   Google Scholar
• Schlapbach C, Hanni T, Yawalker N, et al. Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol. 2011 Oct;65(4):790–798.
   PubMed Web of Science ®Google Scholar
• Kelly G, Hughes R, McGarry T, et al. Dysregulated cytokine expression in lesional and nonlesional skin in hidradenitis suppurativa. Br J Dermatol. 2015 Dec;173(6):1431–1439. .
   PubMedGoogle Scholar
• Kimball a, Jemec G, Okun M, et al. Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo-controlled portion of a phase II, randomized, double-blind study. J Am Acad Dermatol. 2011;64(2):AB155.
   Web of Science ®Google Scholar
• Blok JL, van Hattem S, Jonkman MF, et al. Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systemic review. Br J Dermatol. 2013 Feb;168(2):243–252.
   PubMed Web of Science ®Google Scholar
• Ducroux E, Ocampo MA, Kanitakis J, et al. Hiddradenitis suppurativa after renal transplantation: complete remission after switching from oral cyclosporine to oral tacrolimus. J Am Acad Dermatol. 2014 Nov;71(5):e210–1. .
   PubMed Web of Science ®Google Scholar
• Fardet L, Dupuy a, Delphine K, et al. Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients. J Am Acad Dermatol. 2007 Apr;56(4):624–628. .
   PubMed Web of Science ®Google Scholar
• Adams DR, Gordon KB, Devenyi AG, et al. Severe Hidradenitis Suppurativa Treated With Infliximab Infusion. Arch Dermatol. 2003;139(12):1540–1542.
   PubMedGoogle Scholar
• Sullivan TP, Welsh E, Kerdel FA, et al. Infliximab for hidradenitis suppurativa. Br J Dermatol. 2003 Nov;149(5):1046–1049.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03852472, evaluation of safety and efficacy of avacopan in subjects with moderate to severe hidradenitis suppurativa. Bethesda (MD): National Library of Medicine (US); 2000Feb29; 2019 Feb 25 [cited 2020 Feb 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03852472
   Google Scholar
• Jayne D, Bruchfeld a, Harper L, et al. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol. 2017 Sep;28(9):2756–2767.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03512275, a study of bermekimab in patients with hidradenitis suppurativa. Bethesda (MD): National Library of Medicine (US); 2000Feb29-; 2020 Feb 18 [cited 2020 Feb 19]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03512275
   Google Scholar
• Gottlieb a, Natsis NE, Kerdel F, et al. A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatol. 2020 Jan 29 ;S0022-202X(20)30071–3. published online ahead of print.
   Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03827798, study of efficacy and safety of investigational treatments in patients with moderate to severe hidradenitis suppurativa. Bethesda (MD):National Library of Medicine (US);2000Feb29; 2019 Feb 1 [cited 2020 Feb 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/study/NCT03827798
   Google Scholar
• Espie P, He Y, Koo P, et al. First‐in‐human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti‐CD40 monoclonal antibody. Am J Transplant. 2020 Feb;20(2):463–473. .
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Stan MN, Frommer L, et al. A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-a proof-of-concept trial. J Clin Endocrinol Metab. 2020 Mar 1;105(3). DOI: 10.1210/clinem/dgz013.
   Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03607487, a placebo-controlled study of the safety of INCB054707 in participants with hidradenitis suppurativa. Bethesda (MD): National Library of Medicine (US); 2000Feb29; 2018 Jul 31 [cited 2020 Feb 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03607487
   Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03569371, a study of the safety of INCB054707 in participants with hidradenitis suppurativa. Bethesda (MD): National Library of Medicine (US); 2000Feb29; 2018 Jun 26 [cited 2020 Feb 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03569371
   Google Scholar
• Danto S, Shojaee N, Singh RSP, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06650833, a selective interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, in single and multiple ascending dose randomized phase 1 studies in healthy subjects. Arthritis Res Ther. 2019;21:269.
   PubMed Web of Science ®Google Scholar
• Page KM, Suarez-Farinas M, Suprun M, et al. Molecular and Cellular Responses to the TYK2/JAK1 Inhibitor, PF 06700841, Reveal Reduction of Skin Inflammation in Plaque Psoriasis: TYK2/JAK1 inhibitor in plaque psoriasis. J Invest Dermatol. 2020 Jan 20;pii:S0022-202X(20)30027–0.
   Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT04092452, a study to evaluate the safety and efficacy of PF-06650833, PF-06700841, and PF 06826647 in adults with hidradenitis suppurativa. Bethesda (MD): National Library of Medicine (US); 2000Feb29; 2019 Sep 17 [cited 2020 Feb 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT04092452
   Google Scholar
• Roussomoustakaki M, Dimoulios P, Chatzicostas C, et al. Hidradenitis suppurativa associated with Crohn’s disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol. 2003;38(10):1000–1004.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03099980, exploratory trial evaluating cosentyx (Secukinumab) for patients with moderate-to-severe hidradenitis. Bethesda (MD): National Library of Medicine (US); 2000Feb29. 2017 Apr 4 [cited 2020 Feb 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03099980
   Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03713619, This is a study of efficacy and safety of two secukinumab dose regimens in subjects with moderate to severe hidradenitis suppurativa (HS). Bethesda (MD): National Library of Medicine (US); 2000Feb29. 2018 Oct 22 [cited 2020 Feb 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03713619
   Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03713632, study of efficacy and safety of two secukinumab dose regimens in subjects with moderate to severe hidradenitis suppurativa (HS). Bethesda (MD): National Library of Medicine (US); 2000Feb29. 2018 Oct 22 [cited 2020 Feb 8]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03713632
   Google Scholar
• Deodhar a, Mease PJ, Mcinnes IB, et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data. Arthritis Res Ther. 2019;21:1.
   PubMed Web of Science ®Google Scholar
• Saunte D, Mrowietz U, Puig L, et al. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br J Dermatol. 2017;177(1):47–62.
   PubMed Web of Science ®Google Scholar
• Fala L. Cosentyx (Secukinumab): first IL-17A antagonist receives FDA approval for moderate-to-severe plaque psoriasis. Am Health Drug Benefits. 2016;9(SpecFeature):60–63.
   PubMedGoogle Scholar
• Korzenik J, Larsen MD, Nielsen J, et al. Increased risk of developing Crohn’s disease or ulcerative colitis in 17 018 patients while under treatment with anti-TNFα agents, particularly etanercept, for autoimmune diseases other than inflammatory bowel disease. Aliment Pharmacol Ther. 2019;50(3):289–294.
   PubMed Web of Science ®Google Scholar
• Ehrlich D, Jamaluddin N, Pisegna J, et al. A challenging case of severe ulcerative colitis following the initiation of secukinumab for ankylosing spondylitis. Case Rep Gastrointest Med. 2018;2018:9679287.
   PubMed Web of Science ®Google Scholar
• Marasca C, Megna M, Balato a, et al. Secukinumab and hidradenitis suppurativa: friends or foes? JAAD Case Rep. 2019 Feb;5(2):184–187.
   PubMedGoogle Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT04242446, a study to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (BE HEARD I). Bethesda (MD): National Library of Medicine (US); 2000Feb29. 2018 Oct 22 [cited 2020 Feb 18]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT04242446
   Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT04242498, a study to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (BE HEARD II). Bethesda (MD): National Library of Medicine (US); 2000Feb29. 2018 Oct 22 [cited 2020 Feb 18]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT04242498
   Google Scholar
• ClinicalTrials.gov [Internet]. Identifier NCT03248531, a study to test the efficacy, safety and pharmacokinetics of bimekizumab in subjects with moderate to severe hidradenitis suppurativa. Bethesda (MD): National Library of Medicine (US); 2000Feb29. 2018 Oct 22 [cited 2020 Feb 18]; [about 4 screens]. Available from: https://clinicaltrials.gov/ct2/show/NCT03248531
   Google Scholar
• Yao Y, Thomsen SF. The role of interleukin-17 in the pathogenesis of hidradenitis suppurativa. Dermatol Online J. 2017 Jul 15;23(7).
   PubMedGoogle Scholar
• Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018 Apr;77(4):523–532. .
   PubMed Web of Science ®Google Scholar
• Quartuccio L, Zabotti a, Del Zotto S, et al. Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: usefulness of administrative data. J Adv Res. 2018 Sep;19(15):87–93.
   Google Scholar
• Raaflaub J. The bioavailability of orally administered drugs with special regard to the liver as a filter for foreign matter. Schweiz Med Wochenschr. 1980 Mar 8;110(10):354–362.
   PubMedGoogle Scholar
• Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154:726–729.
   PubMed Web of Science ®Google Scholar